Prior authorization criteria for Wegovy (semaglutide) — cardiovascular event risk reduction
Customize your policy alerts
Sign up for all AvMed policy alerts
Know when AvMed releases new policies or updates existing guidance.
Monitor payer policy activity
This document governs prior authorization and step-edit requests for Wegovy (semaglutide) when prescribed for cardiovascular event risk reduction for AvMed members; it specifies required documentation, clinical criteria for initial and renewal approvals, and administrative submission instructions.
No material clinical or coverage changes in this revision.
Coverage Criteria for Wegovy (semaglutide)
Initial Therapy — Covered when ALL criteria are met for initial authorization
Covered when ALL of the following are met for initial authorization:
chunk 3
chunk 3
chunks 4-5
chunks 4-5
chunk 5
chunk 5
chunk 6
Reauthorization / Continuation Therapy — Covered when ALL criteria are met
Reauthorization covered when ALL of the following are met:
chunk 6
chunk 6
chunk 6
chunk 6
Members are not eligible for approval if they have any of the listed contraindications or exclusionary clinical conditions. Specifically, the member must NOT have New York Heart Association (NYHA) Class IV heart failure symptoms, end-stage renal disease, be receiving dialysis, or have a history of pancreatitis. The request must also confirm the member will not use concurrent therapy with another GLP-1 receptor agonist prescribed for a different indication (examples listed on the form include Mounjaro®, Ozempic®, Trulicity®, and Rybelsus®).
For reauthorization, the provider must attest the member has not newly developed any of these exclusionary conditions since the prior approval. Documentation verifying absence of these conditions should be submitted with the request (e.g., chart notes, labs, or pharmacy claims) as part of the standard supporting documentation required for approval.
Initial Authorization Requirements
Initial authorization — Initial authorization requires meeting all of the following
Initial authorization requires meeting all of the following:
chunk 3
chunk 3
chunk 3
chunks 4-5
chunks 4-5
chunk 5
chunk 6
chunk 5
Reauthorization / Continuation Requirements
Reauthorization requirements — Reauthorization requires documentation of continued benefit and adherence
Reauthorization requires documentation of continued benefit and adherence.
chunk 6
chunk 6
chunk 6
chunk 6
Key Clinical Thresholds & Adherence Metrics
Prior / Background Therapy Requirements
| Requirement | Details |
|---|---|
| Providers must document prior or current use of listed background therapies | |
| Provider must provide clinical rationale why those background therapies are insufficient (submit supporting documentation such as chart notes or pharmacy paid claims) | |
| If comorbid dyslipidemia: member must be on a maximally tolerated statin or, if intolerant, a PCSK9 inhibitor (e.g., evolocumab) or bempedoic acid; provider must explain why lipid‑lowering therapy is inadequate | |
| If comorbid HF or CKD: member must be taking an SGLT2 inhibitor approved for CV risk reduction (e.g., dapagliflozin or empagliflozin); provider must explain why SGLT2 therapy is insufficient | |
| If comorbid T2DM: provider must justify use of semaglutide (Wegovy) versus an SGLT2 and versus semaglutide (Ozempic), explaining why alternatives are not producing sufficient CV risk reduction |
Provider Submission, Documentation, and Administrative Notes
Complete, signed PA/Step-Edit form required
Prescriber must complete and sign the AvMed Pharmacy Prior Authorization/Step-Edit Request form (physician signature required) and fax the completed form with full member and prescriber information to 1-305-671-0200.
Authorizations issued for 12 months — criteria and documentation required
Initial and reauthorization approvals are granted for 12 months and require that all listed clinical criteria are met and supporting documentation is submitted.
Samples do not meet step-edit/preauthorization criteria
Use of drug samples to start therapy does not satisfy the step-edit or prior authorization requirements and will not be accepted as meeting trial/step criteria.
Provide chart notes, labs, diagnostics, and pharmacy claims
Submit objective supporting documentation with the request: chart notes, relevant lab results and diagnostics, and/or pharmacy paid claims to verify diagnosis, prior therapies, and baseline measurements (weight, BMI, height).
- Chart notes verifying established CVD or qualifying events (e.g., prior MI, stroke, symptomatic PAD).
- Lab results or diagnostic reports as applicable (e.g., ABI) and documentation of comorbidity therapies.
- Pharmacy paid claims to verify background guideline-directed CVD therapy, prior/current therapies, and adherence (PDC).
- Baseline measurements: date-stamped weight, height, and BMI.
Incomplete or illegible submissions may delay or be denied
Incomplete, incorrect, or illegible information on the request form (including missing member or prescriber details) can delay processing or result in denial of the authorization.
- Ensure all member identifiers, prescriber name, signature, contact phone/fax, and DEA or NPI are completed legibly.
- Incomplete or missing clinical documentation may lead to denial.
Definitions and Examples
Background & Indication Context
Wegovy (semaglutide) is being requested under this prior authorization pathway specifically for cardiovascular event risk reduction in members with established cardiovascular disease (CVD). The form requires the provider to attest that Wegovy is being used for CV risk reduction and to verify the member’s CVD history in the submitted documentation.
Providers must also document that Wegovy will be used in addition to guideline-directed background CVD therapy unless contraindicated, and must supply clinical rationale when comorbid conditions (for example, HF, CKD, or T2DM) influence the choice of therapy. The request includes baseline measurements (BMI, height, weight) and the provider’s plan to titrate to a maintenance dose of 2.4 mg weekly or 1.7 mg weekly if 2.4 mg is not tolerated.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.